source
- Smith & Nephew lowers 2026 sales outlook as US knee implant revenue falls 7%Smith & Nephew announced a revision to its 2026 sales outlook, now expecting underlying revenue growth of about 4% versus the prior 6% target. The change follows a second‑quarter report showing re…
- Pfizer drops two obesity programs, including Metsera-derived GLP-1 candidate, in pipeline cleanoutPfizer announced it is removing two clinical‑stage obesity programs as part of its quarterly pipeline cleanout. The first program, MET-224o, is an oral ultra‑long‑acting GLP‑1 receptor agonist tha…